1. Home
  2. SES vs RIGL Comparison

SES vs RIGL Comparison

Compare SES & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SES
  • RIGL
  • Stock Information
  • Founded
  • SES 2012
  • RIGL 1996
  • Country
  • SES United States
  • RIGL United States
  • Employees
  • SES N/A
  • RIGL N/A
  • Industry
  • SES Auto Parts:O.E.M.
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • SES Consumer Discretionary
  • RIGL Health Care
  • Exchange
  • SES Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • SES 308.0M
  • RIGL 335.5M
  • IPO Year
  • SES N/A
  • RIGL 2000
  • Fundamental
  • Price
  • SES $0.89
  • RIGL $18.93
  • Analyst Decision
  • SES Hold
  • RIGL Buy
  • Analyst Count
  • SES 3
  • RIGL 5
  • Target Price
  • SES $1.50
  • RIGL $36.40
  • AVG Volume (30 Days)
  • SES 8.5M
  • RIGL 196.7K
  • Earning Date
  • SES 07-28-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • SES N/A
  • RIGL N/A
  • EPS Growth
  • SES N/A
  • RIGL N/A
  • EPS
  • SES N/A
  • RIGL 2.08
  • Revenue
  • SES $7,833,000.00
  • RIGL $203,077,000.00
  • Revenue This Year
  • SES $916.42
  • RIGL $14.41
  • Revenue Next Year
  • SES $151.67
  • RIGL $15.97
  • P/E Ratio
  • SES N/A
  • RIGL $9.09
  • Revenue Growth
  • SES N/A
  • RIGL 70.16
  • 52 Week Low
  • SES $0.20
  • RIGL $7.48
  • 52 Week High
  • SES $2.53
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • SES 47.79
  • RIGL 44.97
  • Support Level
  • SES $0.83
  • RIGL $18.24
  • Resistance Level
  • SES $0.96
  • RIGL $19.35
  • Average True Range (ATR)
  • SES 0.06
  • RIGL 0.90
  • MACD
  • SES -0.01
  • RIGL -0.14
  • Stochastic Oscillator
  • SES 37.86
  • RIGL 23.44

About SES SES AI Corporation

SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: